A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Latest Information Update: 05 Jan 2024
At a glance
- Drugs Cabozantinib (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Clear cell sarcoma; Gastrointestinal stromal tumours; Leiomyosarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
- Focus Therapeutic Use
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 05 Dec 2022 Planned End Date changed from 16 Oct 2022 to 16 Oct 2023.
- 09 Nov 2021 Planned End Date changed from 30 Sep 2021 to 16 Oct 2022.